Evaluation of the efficacy and safety of Co-trimoxazole in patients with COVID-19
Not Applicable
Recruiting
- Conditions
- Coronavirus disease (COVID-19).Severe acute respiratory syndrome [SARS]U07.1
- Registration Number
- IRCT20220407054446N1
- Lead Sponsor
- Bandare-abbas University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Age 18 years or older
Conscious and voluntary satisfaction
Definitive diagnosis of COVID-19 disease by PCR test
Hospitalized with early sign of moderate disease
Exclusion Criteria
Multiple organ failure
Severe ARDS
Septic shock
Acute kidney injury (which GFR is <15)
Drug allergy / Sensitivity to drugs with sulfuric structure / Intolerance to co-trimoxazole
Women during pregnancy and lactation, taking other antiviral drugs, tocilizumab or plasma therapy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction of viral load at the end of the study. Timepoint: At the end of the seventh day or discharge time. Method of measurement: PCR(Polymerase Chain Reaction) test.;Improvement of clinical symptoms during the intervention period (improvement of clinical symptoms as continuous improvement (more than 72 hours). Timepoint: Daily follow up and repeated measurements are performed at least twice per follow up. Method of measurement: Oral temperature = 36.6 °C; respiratory frequency =24 times per minute; and oxygen saturation =98% without mechanical respiration. In addition, the need for oxygen therapy and ventilation with non-invasive positive pressure in daily follow up along with other clinical symptoms such as cough, muscle pain, headache, shortness of breath, weakness and lethargy, decreased sense of smell and taste, diarrhea, abdominal spasm, nausea and vomiting are recorded qualitatively.
- Secondary Outcome Measures
Name Time Method